Lineage Cell Therapeutics, Inc. Financials

Market Capitalization $140.2 Million as of Jan. 1, 2025

Valuations Metrics as of May. 5, 2024

Trailing PE
Forward PE	-8.15
Price to Sales TTM	$22.37
Price to Book MRQ	$2.93
Enterprise to Revenue	18.55
Enterprise to EBITDA	-8.09

Financial Reports as of Dec. 31, 2023

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2023-12-31
Profit Margin	-240.20%
Operating Margin	-135.63%
Return on Assets TTM	-11.80%
Return on Equity TTM	-32.07%

Income Statement

Revenue TTM	$8,945,000
Revenue per Share TTM	$0.05
Quarterly Revenue Growth	9.00%
Gross Profit TTM	$8,274,000
EBITDA	$-20,511,000
Net Income to Common TTM	$-21,486,000
Diluted EPS TTM	$-0.12
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	$35,492,000
Total Cash per Share MRQ	$0.19
Total Debt MRQ	$
Total Debt to Equity MRQ	4.76
Current Ratio MRQ	2.14
Book Value per Share MRQ	$0.36

Cash Flow

Operating Cash Flow TTM	$-28,566,000
Levered Free Cash Flow TTM	$-10,368,875

LCTX Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding	188,798,000
Float Shares	146,105,949
Avg 10 Volume	638,628
Avg 30 Volume	None
Shares Short	10,582,768
Short Ratio	9.33
Short % of Shares	7.56%
% Held by Insiders	0.43%
% Held by Institutions	43.94%

Stock Price Summary

Beta	1.33
Fifty Two Week Low	$0.84
Fifty Two Week High	$1.61
Fifty Two Week Change	-40.57%
Day 50 MA	$1.22
Day 200 MA	$1.19

Dividends and Splits

Forward Annual Dividend Rate	$1.25
Forward Annual Dividend Yield	117.92%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date	2016-01-04
Last Split Factor
Last Split Date	1997-10-31